Cell and Gene Therapy Market is predicted to reach USD 67.89 billion at a CAGR of 18.12% during the forecast period 2023-2032

Market Research Future (MRFR) has published on the “Global Cell and Gene Therapy Market”.

The Cell and Gene Therapy Market is estimated to register a CAGR of 18.12% during the forecast period of 2024 to 2032.

MRFR recognizes the following companies as the key players in the Global Cell and Gene Therapy Market - Novartis AG (Switzerland), Bristol-Myers Squibb Company (US), Amgen Inc. (US), Aurion Biotech (US), Sarepta Therapeutics, Inc. (US), Ferring B.V. (Switzerland), Sibiono Genetech Co, Ltd., Shenzhen (Sibiono), Bluebird Bio, Inc. (US), Kite Pharmaceuticals, Inc. (US), Janssen Global Services (US)

Cell and Gene Therapy Market Highlights

The global Cell and Gene Therapy Market is expected to register a CAGR of 18.12% during the forecast period and is estimated to reach USD 67.89 billion by 2032.

The global Cell and Gene Therapy Market is emerging due to the Increasing incidences of diseases such as cancer, cystic fibrosis, sickle cell anemia, and others and increasing approval for gene and cell therapy products. Additionally, the growing technological advancements and innovation will provide growth opportunities for the market in the future.

Segment Analysis

The global Cell and Gene Therapy Market has been segmented based on Therapy Type and Application

Based on therapy type, the global cell & gene therapy market has been segmented into cell therapy and gene therapy. The cell therapy segment held the largest market share in 2023 and gene therapy is the fastest-growing segment during the forecast period i.e., 2024 -2032.

Gene therapy segment is further segmented into Autologous and Allogenic. The autologous segment dominated the market in 2023. Additionally, it is anticipated that during the forecast period, this segment will increase more quickly. Due to the widespread use of CAR-T treatments and their successful outcomes in the treatment of various malignancies and genetic abnormalities, the market is expected to rise.

The gene therapy segment is further segmented into Ex-vivo and In-vivo. The in vivo therapy segment held the largest market share in 2023, owing to increase in the adoption of in vivo gene therapies globally. As vivo gene therapy can reach multiple sites or organs throughout the body, it allows for systemic treatment. This is especially beneficial for diseases that affect multiple organ systems or have systemic manifestations, allowing for a more comprehensive therapeutic approach.

Based on application, the global cell & gene therapy market has been segmented into Cancer, Neurological Disorders, Cardiovascular Disorders, Rare Diseases, Ophthalmology, Blood Disorders, and Others. The cancer segment held the largest market and is the fastest growing segment during the forecast period, owing to increase in prevalence of cancer, rise in development of gene and cell therapy drugs specific to oncology.  Advances in gene editing technologies such as CRISPER-CAS9, TALEN, and zinc finger nucleases, enable precise modifications of gene in immune cells to enhance their anti-cancer properties. These technologies can be used to knock out the genes that inhibit immune responses or to introduce genes that enhance cytotoxicity against cancer cells. For instance, in 2022, the US Food and Drug Administration (FDA) approved Adstiladrin (nadofaragene firadenovec-vncg) in December 2022, new long-term follow up data has been revealed.

Explore In-depth Market Details [Table of Content, List of Figures, List of Tables] of Cell and Gene Therapy Market Research Report

Regional Analysis

By Region, the study segments the market into North America, Europe, Asia-Pacific, and Rest of the World.

Based on region, the global cell & gene therapy market has been segmented into North America, Europe, Asia-Pacific, and the Rest of the World. North America accounted for the largest market share of 42.68% in 2023 and is anticipated to reach approximately USD 27.01 billion by 2032 at a 17.38% CAGR during the forecast period, owing to rise in the prevalence of chronic disease, availably of reimbursements for the gene therapy and rise in healthcare expenditure and research development activities for gene therapy drugs across the region. In North America, US dominated the market with market share of 82.36%.

However, Asia-Pacific is projected to grow at the highest CAGR of 20.10% during the forecast period, owing to a sizable population base, heightened healthcare awareness, and a surge in cases of cancer. These factors collectively drive the demand for gene therapy in the region. Additionally, pharmaceutical market expansion, government initiatives, and a surge in research and development activities contribute to the region's accelerated growth. Furthermore, a rise in research activities as well as the well-established presence of domestic companies in the region are expected to provide notable opportunities for market growth. Asia-Pacific is further segmented into the China, India, Japan, South Korea, Australia, and Rest of Asia-Pacific. Japan dominated the market in Asia-Pacific region with market share 24.55%.

Key Findings of the Study

• The global Cell and Gene Therapy Market is expected to reach USD 67.89 billion by 2032, at a CAGR of 18.12% during the forecast period.


• The North America Global Cell and Gene Therapy market accounted for USD 5.44 billion in 2023 and is expected to exhibit a 17.38% CAGR during the study period.


• Based on therapy type, The cell therapy segment held the majority share in 2023.


• Novartis AG (Switzerland), Bristol-Myers Squibb Company (US), Amgen Inc. (US), Aurion Biotech (US), Sarepta Therapeutics, Inc. (US), Ferring B.V. (Switzerland), Sibiono Genetech Co, Ltd., Shenzhen (Sibiono), Bluebird Bio, Inc. (US), Kite Pharmaceuticals, Inc. (US), Janssen Global Services (US) are the key market players.